Dose Ranging Study of Carbidopa-levodopa

Overview

From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD, and measure the effects on visual acuity and retinal abnormalities due to "wet" (neovascular) AMD. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD who are already on treatment with anti-VEGF intraocular injections, and measure the effects on visual acuity, retinal abnormalities due to "wet" AMD, and document the number of anti-VEGF injections required during the study.

Age-related macular degeneration (AMD) is the most common cause of blindness, in individuals over the age of 50, in the developed world. AMD becomes more common as people age and is more common in lightly pigmented individuals. AMD appears more common in patients with Parkinson's Disease than in those without. The AREDS nutritional supplements are effective in slowing the progress of intermediate AMD(5). Most AMD is "dry AMD", which progresses relatively slowly and may impair vision, but usually does not lead to legal blindness. There are two forms of AMD, "wet AMD" and geographic atrophy (GA), that can cause more profound vision loss. In aggregate, they occur in about 25% of patients with AMD. Wet AMD is due to new growth of abnormal blood vessels under the retina. The new blood vessels are believed to be due to an excessive release of vascular endothelial growth factor (VEGF) by the retinal pigment epithelium(RPE) cells. Wet AMD is now effectively treated with intraocular injections of VEGF inhibitors. Geographic Atrophy, the other form of advanced AMD, represents focal death of the RPE cells and overlying neurosensory retina. There is no current treatment for GA. It is suspected that GA is due in part to a localized inflammatory response, damage to RPE cells, and loss of RPE cell function. It may also be speculated that stimulation of RPE cells to release a potent neurotrophic factor, pigment epithelium derived factor (PEDF) may slow the progression of GA. In 2008, Dr. Brian McKay identified a receptor, G protein coupled receptor #143(GPR143), on the surface of RPE cells and discovered that L-DOPA was the natural ligand or stimulator of GPR143. Dr. McKay showed that treatment of RPE cells with exogenous L-DOPA resulted in the release of additional PEDF. In subsequent work, Dr. McKay's group also showed that L-DOPA stimulation of PEDF in RPE cells was also associated with a decrease in VEGF. Thus, Dr McKay hypothesized that exogenous L-DOPA may prevent the onset of AMD or progression to wet AMD. In 2015, Dr McKay and his associates published a paper that showed that patients, who had been treated with L-DOPA, had a delay in the onset of AMD by 8 years, compared to patients who had not been treated with L-DOPA. In addition, those who had AMD and went on to develop wet AMD did so 5 years later than those with no history of L-DOPA treatment. L-DOPA is an intermediate in the pigmentation pathway. Dr. McKay and his associates suggested that the reason darkly pigmented races do not get AMD nearly as frequently as lighter-pigmented races is that they produce more pigment, and thus more L-DOPA to stimulate GPR143 on RPE cells. According to this hypothesis, the stimulated RPE cells release PEDF and decrease VEGF, which together are responsible for the protective effect. Pharmacology of L-DOPA and carbidopa: L-DOPA is formed by 3-hydroxylation of tyrosine by tyrosine-3-monooxygenase (tyrosinase).(18) The primary metabolic pathway of L-DOPA is decarboxylation by amino acid decarboxylase to dopamine, which is responsible for most, but not all, of its pharmacologic effects and toxicity. When carbidopa is administered with L-DOPA, systemic levels of L-DOPA double, and central nervous system (CNS) L-DOPA increases from about 1% of the administered dose to about 4%. Levodopa freely passes from the systemic circulation into the retina and brain, but dopamine and carbidopa do not. Adverse events are markedly decreased when carbidopa is administered with L-DOPA, because systemic levels of the toxic metabolite of L-DOPA, dopamine, are markedly reduced. In most patients, 25 mg of carbidopa is sufficient to control side effects of 100 mg of L-DOPA, primarily nausea, by 90%. L-DOPA is the natural ligand for GPR143 in the RPE cells. The Investigators' intent is to increase the L-DOPA available to RPE surface receptors (GPR 143) while minimizing peripheral toxicity. This concept is unique, because all other uses of L-DOPA rely on CNS conversion of L-DOPA to dopamine, in order to produce the desired effect. Pathogenesis of Neovascular AMD. Excess VEGF is the mediator of retinal neovascularization and other retinal pathological changes in "wet" AMD. Intraocular injections of anti-VEGF antibodies is the standard of care in "Wet" AMD. Several publications, including Lim et al, show that with careful monitoring of the visual acuity and retinas of patients with wet AMD, if there is no progression, there are no long-term adverse consequences of delaying initiation of anti-VEGF therapy for up to 4 weeks. The patients will all have had anti-VEGF therapy initiated. The patients will be monitored at monthly intervals, for up to 3 months, for indications for administration of anti-VEGF injections. Since there are no established animal models for AMD, and L-DOPA has a good safety profile in healthy volunteers and patients with Parkinson's disease, the Investigators propose a prospective experiment to determine the safety and tolerability of L-DOPA, in a population of patients with AMD. The participants will be made aware of potential side effects of L-DOPA, which are listed in the Informed Consent, during the consent process. Adverse events will be elicited by questioning the participants at each visit. The participants will also be advised to call the site if they have any medical problems between visits. The Investigators will also use this study to examine whether L-DOPA has a positive effect on visual acuity and pathologic retinal changes of "wet" AMD. The parameters to be evaluated are best corrected ETDRS visual acuity, macular thickness by spectral domain optical coherence tomography (SD OCT), new blood (hemorrhage) by direct retinal examination, or subjective decrease in vision. Treatments: Patients will receive open-label, commercially available carbidopa-levodopa 25-100 mg, one tablet once daily hs for one month, followed by one tablet dosed TID (three times daily), in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg). Patients entering this study after completing Study 001 will receive one month of the dose that he or she received in Study 001, and one month each of any doses higher than the dose that he or she received in Study 001. Examples: 1. If the patient received carbidopa-levodopa 25-100 mg once daily in Study 001, he or she will receive one month of treatment with each of the 3 daily doses of carbidopa-levodopa. 2. If the patient received carbidopa-levodopa 25-100 mg TID in Study 001, he or she will receive one month of carbidopa-levodopa 25-100 mg TID, followed by one month of carbidopa-levodopa 25-100 mg, 2 tablets TID. Each patient will receive an injection of anti-VEGF medication on the day carbidopa-levodopa dosing begins in this study. Each patient will be evaluated at monthly (25-35 day) intervals and injected or not, based upon the criteria listed below, which are based on clinical practice standard of care. Criteria for anti-VEGF injections All patients will have had at least one anti-VEGF intraocular injection prior to entering the study. Additional injections will be based on: monthly evaluation of ETDRS (Early Treatment Diabetic Retinopathy Study), visual acuity (decrease of 5 letters from previous visit); increased macular thickness (compared to normal and previous visit as measured by SD OCT; new blood (hemorrhage) on direct retinal examination; or subjective decrease in vision. If any of these criteria are met, or if, in the opinion of the Ophthalmologist, the patient requires anti-VEGF therapy, the patient will have an anti-VEGF intraocular injection. If none of these criteria are met at visits 2, 3, or 4, with patient agreement, anti-VEGF injection will not be done, and the patient will be reevaluated in 1 month. The study will end at Visit 5, and patients will begin standard of care treatment with anti-VEGF injections. Patients who have completed Study 0001, Short-term effects of carbidopa-levodopa in Neovascular AMD, will be eligible to enroll in the current study, Study 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. Number of subjects: 52 completed Duration: up to 112 days of treatment. Primary Endpoint: A statistically significant improvement (5 letters) by carbidopa-levodopa treatment in ETDRS visual acuity. Measurements and Activities: 1. Informed Consent at Baseline; 2. Ophthalmic history and comprehensive eye examination; including visual acuity, wearing any prescription lenses, using an EDTRS chart, in both eyes prior to randomization, and ophthalmoscopic examination, and SD OCT; 3. Repeat assessment of visual acuity using an EDTRS chart, ophthalmoscopic examination, and SD OCT at monthly visits; 4. Demographics at Baseline; 5. Medical History, Vital Signs and Physical Examination at Baseline; 6. ECG, CBC (complete blood count), Chem 20 and HbA1C at Baseline; 7. Dispense study medication at visits 2, 3 and 4; 8. Pill count at visits 3, 4 and 5; 9. Non-directed assessment of adverse events at each visit, including classification as to severity, seriousness and body system. 10. Concomitant medications at each visit. 11. If a patient had the baseline evaluation in Study 001, that will be used as the baseline evaluation for this study. Statistics: Descriptive statistics will be generated for, at a minimum, ETDRS visual acuity, central retinal thickness, amount of intraretinal and subretinal fluid and presence of hemorrhage. Within patient trajectories for these outcomes will be plotted, incorporating information on dose and duration. Due to the small sample size, model-based analyses will be considered only to be exploratory. Analysis of Variance may be conducted to relate logarithm of dose and duration of treatment to the outcomes listed above.